Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone/Bupropion and Mediterranean Diet in Obese Breast Cancer Survivors
NCT03581630Completed
- Sponsor
- Gangnam Severance Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of naltrexone + bupropion in obesity (3 arms), sponsored by Gangnam Severance Hospital. Primary endpoints: Change in body weight at 8 weeks, Change in fat mass at 8 weeks and 6 more. Started Jul 2017; status: completed.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03581630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581630.